Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara

Sunshine Lake Pharma, Lannett and its wholly owned subsidiary Lanexa Biologics have received FDA approval for Langlara. Langlara is manufactured by Sunshine Lake Pharma, part of the HEC Group and commercialised in the US via Lanexa Biologics. The FDA decision followed studies showing Langlara matched Lantus in pharmacokinetics, efficacy, safety, and immunogenicity for diabetes. Credit: Lannett Company / Business Wire. Sunshine Lake Pharma, Lannett and its wholly owned subsidiary Lanexa Biologics have received approval from the US Food and Drug Administration (FDA) for Langlara (insulin glargine-aldy), an interchangeable biosimilar of Lantus (insulin glargine). Langlara is cleared for use in adults…

Source: Pharmaceutical Technology